CBMT17006 / A051301 / Michael Becker
Research Question:
What are the good and/or bad effects of using an oral medication, ibrutinib, along
with the autologous hematopoietic stem cell transplantation (AutoHCT) versus AutoHCT
alone?
Basic Study Information
Purpose:
This randomized phase III trial studies ibrutinib to see how well it works compared
to placebo when given before and after stem cell transplant in treating patients with
diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed)
or does not respond to treatment (refractory). Before transplant, stem cells are taken
from patients and stored. Patients then receive high doses of chemotherapy to kill
cancer cells and make room for healthy cells. After treatment, the stem cells are
then returned to the patient to replace the blood-forming cells that were destroyed
by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells
by blocking a protein that is needed for cell growth. It is not yet known whether
adding ibrutinib to chemotherapy before and after stem cell transplant may help the
transplant work better in patients with relapsed or refractory diffuse large B-cell
lymphoma.
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02443077?term=a051301&rank=1
Study Reference #: CBMT17006
Lead Researcher (Principal Investigator)
Lead Researcher:
Michael Becker, MD
Study Contact Information
Study Coordinator: Jessica Mackowiak
Email: jessica_ellis@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search